Protagonist Therapeutics to replace Encore Wire in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA is acquiring Encore Wire in a deal expected to be completed soon pending final conditions.
Protagonist Therapeutics To Join S&P SmallCap 600, Effective Prior To Opening Of Trading On July 3
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.